Geode Capital Management LLC Trims Position in ANI Pharmaceuticals, Inc. $ANIP

Geode Capital Management LLC reduced its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 0.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 427,546 shares of the specialty pharmaceutical company’s stock after selling 2,080 shares during the period. Geode Capital Management LLC owned about 1.97% of ANI Pharmaceuticals worth $27,901,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ANIP. Global Alpha Capital Management Ltd. lifted its position in ANI Pharmaceuticals by 17.2% during the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after purchasing an additional 126,500 shares during the period. Aberdeen Group plc raised its stake in shares of ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock valued at $28,059,000 after buying an additional 181,134 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock valued at $15,959,000 after buying an additional 2,220 shares during the period. Nomura Holdings Inc. boosted its stake in shares of ANI Pharmaceuticals by 1.5% in the first quarter. Nomura Holdings Inc. now owns 217,176 shares of the specialty pharmaceutical company’s stock worth $14,540,000 after buying an additional 3,297 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of ANI Pharmaceuticals by 6.1% in the first quarter. Northern Trust Corp now owns 216,862 shares of the specialty pharmaceutical company’s stock worth $14,519,000 after buying an additional 12,517 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ANIP shares. Piper Sandler reissued an “overweight” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Finally, JPMorgan Chase & Co. upped their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $99.29.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $87.27, for a total value of $34,908.00. Following the transaction, the vice president owned 75,274 shares in the company, valued at approximately $6,569,161.98. This trade represents a 0.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Friday, September 19th. The stock was sold at an average price of $98.04, for a total transaction of $98,040.00. Following the sale, the senior vice president directly owned 60,186 shares of the company’s stock, valued at $5,900,635.44. The trade was a 1.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 32,871 shares of company stock valued at $2,963,993. 11.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ ANIP opened at $84.88 on Friday. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -110.23 and a beta of 0.54. The company’s 50-day simple moving average is $89.68 and its 200-day simple moving average is $78.97. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. During the same quarter in the prior year, the firm earned $1.34 EPS. The company’s revenue for the quarter was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.